**Name of journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO: 8782**

**Columns: ORIGINAL ARTICLE**

**Correlation between hepatic blood flow and liver function in alcoholic liver cirrhosis**

Takahashi H *et al*. Hepatic blood flow and liver function

Hideaki Takahashi, Ryuta Shigefuku, Yoshihito Yoshida, Hiroki Ikeda, Kotaro Matsunaga, Nobuyuki Matsumoto, Chiaki Okuse, Shigeru Sase, Fumio Itoh, Michihiro Suzuki

**Hideaki Takahashi, Ryuta Shigefuku, Yoshihito Yoshida, Hiroki Ikeda, Kotaro Matsunaga, Nobuyuki Matsumoto, Chiaki Okuse, Fumio Itoh, Michihiro Suzuki,** Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University, Kawasaki 216-8511, Japan

**Hideaki Takahashi,**Division of Gastroenterology, Department of Internal Medicine, Sapporo Shirakabadai Hospital, Sapporo 062-0052, Japan

**Hideaki Takahashi,** Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo 060-8556, Japan

**Shigeru Sase,** Anzai Medical Co., Ltd., Tokyo 141-0033, Japan

**Author contributions:** Takahashi H and Shigefuku R contributed equally to this article; Takahashi H contributed to the study concept and design; Takahashi H, Shigefuku R, Yoshida Y, Ikeda H, Matsunaga K, Matsumoto N, Okuse C and Sase S contributed to the acquisition of data; Takahashi H, Shigefuku R and Yoshida Y contributed to the analysis and interpretation of data; Takahashi H drafted the article or revised it critically for important intellectual content; Takahashi H and Shigefuku R contributed to the statistical analysis.

**Correspondence to: Hideaki Takahashi, MD, PhD,** Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1 Sugao Miyamae-ku, Kawasaki 216-8511, Japan. hide-bo@marianna-u.ac.jp

**Telephone:** +81-44-9765805 **Fax:** +81-44-9765805

**Received:** January 6, 2014 **Revised**: March 31, 2014

**Accepted:** April 27, 2014

**Published online:**

**Abstract**

**AIM**: To elucidate the correlation between hepatic blood flow and liver function in alcoholic liver cirrhosis (AL-LC).

**METHODS**: The subjects included 35 patients with AL-LC (34 men, 1 woman; mean age, 58.9 ± 10.7 years; median age, 61 years; range 37–76 years). All patients were enrolled in this study after obtaining written informed consent. Liver function was measured with tests measuring albumin (Alb), prothrombin time (PT), brain natriuretic peptide (BNP), branched amino acid and tyrosine ratio (BTR), branched chain amino acid (BCAA), tyrosine, ammonia (NH3), cholinesterase (ChE), immunoreactive insulin (IRI), total bile acid (TBA), and the retention rate of indocyanine green 15 min after administration (ICG R15). Hepatic blood flow, hepatic arterial tissue blood flow (HATBF), portal venous tissue blood flow (PVTBF), and total hepatic tissue blood (THTBF) flow were simultaneously calculated using xenon computed tomography.

**RESULTS**: PVTBF, HATBF and THTBF are 30.2 ± 10.4, 20.0 ± 10.7, 50.3 ± 14.9, respectively. Alb, PT, BNP, BTR, BCAA, tyrosine, NH3, ChE, IRI, TBA, and ICG R15 are 3.50 ± 0.50, 72.0 ± 11.5, 63.2 ± 56.7, 4.06 ± 1.24, 437.5 ± 89.4, 117.7 ± 32.8, 59.4 ± 22.7, 161.0 ± 70.8, 12.8 ± 5.0, 68.0 ± 51.8, 28.6 ± 13.5, respectively. PVTBF showed a significant negative correlation with ICG R15 (*r* = -0.468, *P*<0.01). No significant correlation was seen between ICG 15R, HATBF and THTBF. There was a significant correlation between PVTBF and Alb (*r* = 0.2499, *P* < 0.05), and NH3 tended to have an inverse correlation with PVTBF (*r* = -0.2428, *P* = 0.0894). There were also many significant correlations between ICG R15 and liver function parameters, including Alb, NH3, PT, BNP, TBA, BCAA, and tyrosine (*r* = -0.2156, *P* < 0.05; *r* = 0.4318, *P* < 0.01; *r* = 0.4140, *P* < 0.01; *r* = 0.3610, *P* < 0.05; *r* = 0.5085, *P* < 0.001; *r* = 0.4496, *P* < 0.01; and *r* = 0.4740, *P* < 0.05, respectively).

**CONCLUSION**: Our investigation showed that there is a close correlation between liver function and hepatic blood flow.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words:** Alcoholic liver cirrhosis; Hepatic tissue blood flow; Liver function; Indocyanine green; Xenon computed tomography

**Core tip:** Hepatic blood flow (HBF) generally decreases with disease progression inchronic liver disease. Additionally collateral vessel appear and liver function, such as liver synthesis and disposal capability, declines in liver cirrhosis (LC). Notably in LC it is known that liver function deteriorates in almost direct proportion to progression of liver disease such as Child-Pugh classification. Thus, in order to assess the state of chronic liver disease it is very important to evaluate HBF. The aim of the present study was to measure liver function and HBF using xenon computed tomography, and elucidate the correlation between HBF and liver function in alcoholic LC.

Takahashi H, Shigefuku R, Yoshida Y, Ikeda H, Matsunaga K, Matsumoto N, Okuse C, Sase S, Itoh F, Suzuki M. Correlation between hepatic blood flow and liver function in alcoholic liver cirrhosis. *World J Gastroenterol* 2014; In press

**INTRODUCTION**

In general, liver function gradually deteriorates as chronic liver disease (CLD) progresses. Notably in patients with liver cirrhosis (LC), liver function deteriorates in almost direct proportion to liver disease progression such as an increase in Child-Pugh classification. Additionally, hepatic blood flow (HBF) gradually decreases as CLD progresses. Thus, to assess the state of CLD, it is very important to evaluate HBF. However, it is difficult to evaluate HBF because the liver receives blood from both the portal vein and hepatic artery, and these systems are known to use independent mechanisms for blood flow adjustment.

 Xenon computed tomography (Xe-CT) is a convenient and noninvasive method combining xenon gas inhalation with CT to quantify and visualize tissue blood flow (TBF). It is widely used in neurosurgical practice to evaluate cerebral TBF[1,2]. Xe-CT can also be used to obtain separate noninvasive measurements of hepatic arterial tissue blood flow (HATBF) and portal venous tissue blood flow (PVTBF) to detect changes in HBF caused by CLD progression[3-13]. Xe-CT using a dual blood supply model has been used to evaluate HATBF and PVTBF separately[3,8,9]. HBF obtained by Xe-CT corresponds to TBF, not intravascular blood flow because Xe gas can penetrate the hepatocytes. HBF can be obtained by other modalities such as perfusion CT, perfusion magnetic resonance imaging (MRI), and enhanced ultrasound, and these are the methods used to measure intravascular blood flow in the liver.

 Recently, HBF has been evaluated using various noninvasive methods such as ultrasonography (US), computed tomography (CT), and magnetic resonance imaging (MRI). In methods such as color Doppler US[14-17] and angiography[18], intravascular HBF is calculated by measuring flow velocities and vessel diameters of the portal vein and hepatic artery. Furthermore, TBF measurement has been attempted using enhanced CT and MRI[14,19,20]. Hepatic TBF has been evaluated in patients with CLD using Xe-CT[3-13].

 Hepatic blood flow (HBF) generally decreases with disease progression in chronic liver disease. There are many reports about corelation between HBF and severity of liver disease, especially LC. Additionally collateral vessel appear and liver function, such as liver synthesis and disposal capability, declines in liver cirrhosis (LC). Thus, in order to assess the state of CLD it is very important to evaluate HBF. However correlation between HBF and liver function remain unclear. This study aimed to measure liver function and HBF using Xe-CT and to elucidate the correlation between HBF and liver function in alcoholic LC (AL-LC).

**MATERIALS AND METHODS**

***Patients***

 Between October 2001 and September 2012, we performed Xe-CT on 556 patients. Of 556 patients, 35 with AL-LC (34 men, 1 woman; mean age, 58.9 ± 10.7 years; median age, 61 years; range 37–76 years) who provided written informed consent in advance were enrolled in this study (Table 1). At least they have no severe heart, renal and respiratory disease apart from liver cirrhosis. After confirmation of the above criteria and absence of hepatocellular carcinoma to exclude the influence of intrahepatic flow, Xe-CT was performed on admission. All study protocols were conducted in accordance with the ethics guidelines of the Declaration of Helsinki and approved by the ethics committee at our institution (approval No. 480).

***Xe-CT theory***

 Xe is an inert gas that is present in the atmosphere in trace amounts. A high atomic weight and x-ray mass absorption coefficient for the element Xe facilitate the measurement of changes in tissue concentrations of Xe with CT. In Xe-CT, changes in Xe concentrations over time are measured in the hepatic tissue and spleen. By applying the Fick principle[21], a single blood supply model (inflow: arterial only, outflow: venous) can be fitted to a dual blood supply model (inflow: arterial and portal venous) to separately determine HATBF (mL/100 mL/min) and PVTBF (mL/100 mL/min) (Figure 1). Total hepatic tissue blood flow (THTBF) is the sum of HATBF and PVTBF.

***Xe-CT imaging protocol***

The imaging devices, protocol, and processing were the same as previously reported[9,10]. We used 25% stable Xe gas in conjunction with an AZ-726 Xe gas inhalation system (Anzai Medical Co., Ltd., Tokyo, Japan). The wash-in and wash-out periods were both 4 min. The entire liver was examined by CT at 1-min intervals at 4 levels, including the porta hepatis (9 scans in total, including the baseline scan) (Figure 2). Using an AZ-7000W image processing system (Anzai Medical Co., Ltd.), PVTBF, HATBF, and THTBF were calculated, and these maps were created. The time course change rate for the arterial Xe concentration, which was needed to calculate PVTBF and HATBF, was derived using the time course of the Xe concentration in the spleen tissue. An Aquilion CT scanner (Toshiba Medical Systems Corporation, Tokyo, Japan) was used, with exposure factors of 120 kV, 150 mA, and 13.8 mGy. Confidence values indicated the difference between theoretical and actual changes in CT values over time and were used as an index of reliability (Figure 3). Regions of interest (ROI) were chosen at 4 levels, and areas with low reliability were automatically excluded (Figure 3). The mean of the 4 levels was used to determine PVTBF and HATBF in each patient, and THTBF was calculated as the sum of PVTBF and HATBF (Figure 4). Xe-CT was performed on admission. The analysts of the Xe-CT data were blinded to the results of the clinical information.

***Liver function and ICG R15***

Liver function tests were measured on admission. Liver function tests included the following parameters: albumin (Alb) (g/dL), prothronbin time (PT) (%), brain natriuretic peptide (BNP) (pg/mL), branched amino acid and tyrosine ratio (BTR), branched chain amino acid (BCAA) (μmol/L), tyrosine (μmol/L), ammonia (NH3 μg/dL), cholinesterase (ChE IU/L), immunoreactive insulin (IRI μU/mL), total bile acid (TBA μmol/L), and the retention rate of indocyanine green 15 min after administration (ICG R15) (%). ICG (Diagnogreen®, Daiichi Sankyo Co., Tokyo, Japan; 0.5 mg/kg body weight) was administered via a peripheral vein, and venous blood was sampled before and 15 min after injection. Specimens were analyzed for ICG concentrations on a spectrophotometer at 805 nm.

***Statistical analysis***

Each parameter is expressed as mean ± standard deviation (SD). The Pearson product-moment correlation coefficient was used to examine correlations between TBF parameters and liver function tests. The Pearson product-moment correlation coefficient is a measure of the linear correlation between two variables. It is defined as covariance of the two variables divided by the product of standard deviations. All statistical tests were performed with the statistical software, GraphPad Prism (GraphPad Software, Inc., La Jolla, California, United States). *P* values < 0.05 were considered statistically significant.

**RESULTS**

***Hepatic TBF, ICG R15, and liver function***

 Hepatic TBF as measured by Xe-CT, ICG R15, and liver function is summarized in Table 2.

***Correlation between hepatic TBF and ICG R15***

PVTBF showed a significant negative correlation with ICG R15 (*r* = -0.468, *P* < 0.01, Figure 5). No significant correlation was seen between ICG 15R and HATBF and THTBF.

***Correlation between hepatic TBF, ICG R15 and liver function***

The correlations between hepatic TBF as measured by Xe-CT, ICG R15, and liver function are summarized in Table 3, Figure 6, and Figure 7. There was a significant correlation between PVTBF and Alb (*r* = 0.2499, *P* < 0.05), and NH3 tended to have an inverse correlation with PVTBF (*r* = -0.2428, *P* = 0.0894) (Table 3 and Figure 6). There were also many significant correlations between ICG R15 and liver function parameters, including Alb, NH3, PT, BNP, TBA, BCAA, and tyrosine (*r* = -0.2156, *P* < 0.05; *r* = 0.4318, *P* < 0.01; *r* = 0.4140, *P* < 0.01; *r* = 0.3610, *P* < 0.05; *r* = 0.5085, *P* < 0.001; *r* = 0.4496, *P* < 0.01; and *r* = 0.4740, *P* < 0.05, respectively) (Table 3 and Figure 7).

**DISCUSSION**

Some methods can be used to measure HBF include organ-reflectance spectrophotometry and hydrogen clearance[22,23], direct catheter insertion[18,24], continuous spectral Doppler US[16,17], dynamic CT[20], and dynamic MRI[14]. HBF gradually decreases as liver disease progresses in all patients with CLD including alcoholic liver disease[7,9,16,17,20,22,23], nonalcoholic fatty liver disease[8,9,12,13], and liver disease related to hepatitis C virus[6,7,9,13].

 Liver function gradually deteriorates as CLD progresses. In particular, liver function deteriorates in almost direct proportion to liver disease progression in patients with LC. Additionally, a hyperdynamic state appears as CLD progresses, especially in LC, and total plasma volume gradually increases[24]. In the portal venous system, including the celiac artery and superior mesenteric artery, in particular, splenic arterial flow prominently increases and accounts for a considerable amount of the portal venous system volume[24]. Conversely, HBF generally decreases with disease progression[16-18,20,22,23,27], and we have reported results similar to those previously reported[6-9,12]. In addition, portal flow decreases in inverse proportion to ICG R15[14,20]. We also previously reported that portal flow gradually decreases in patients with LC as the Child-Pugh score increases or disease stage advances[7,9]. Berzigotti reported that HBF estimations by Doppler US and ICG are significantly correlated[28]. This study showed that ICG R15 can be a more valuable and precise index that reflects both HBF and liver function because there were many significant correlations between ICG R15 and liver function in our investigation. Presently, we have a renewed sense of the importance of ICG R15.

 In general, portal/hepatic arterial flow ratio (P/A) is approximately 2[29]. However, there is a compensatory mechanism called the hepatic arterial buffer response[24-27], which maintains total HBF by increasing hepatic arterial flow in response to decreasing portal flow[24-27]. This hepatic hemodynamic alteration, particularly the decrease of portal flow, causes collateral vessel development, especially the emergence of esophagogastric varices (EGV). The portal vein acts as a functional vessel, and the hepatic artery acts as a feeding vessel[29]. Portal flow transports, fatty acid, glycerin, glucose, amino acid, and other compounds on one hand, and, bilirubin, ammonia, aromatic amino acid, and other compounds on the other hand into the hepatocytes to metabolize. One is to synthesize and the other is to discard. Portal flow is important in metabolism. In this study, unlike HATBF and THTBF, PVTBF had a stronger correlation with liver function and disease status. PVTBF has predominance and plays an important role in HBF. Furthermore, PVTBF has an active hemodynamic change. Conversely, HATBF has a passive hemodynamic change.

 Generally, when HBF decreases, a compensatory mechanism is called upon for O2 concentration maintenance. This results in an increase of O2 extraction (oxygen desaturation). However, if HBF further decreases, that mechanism cannot compensate adequately for O2 concentration maintenance, and a decrease in oxygen consumption follows[22,23]. The decrease in HBF and oxygen consumption induces oxidant stress and cytokines that trigger inflammation. As a consequence, fibrosis progresses and HBF further decreases, thus creating a vicious cycle[23]. As CLD progresses, liver synthesis and disposal capability decline. Hayashi *et al*[22] reported a significant positive correlation between HBF and local oxygen consumption in alcoholic liver disease and low levels of HBF and local oxygen consumption (even in the alcoholic fatty liver), which gradually decreased as CLD progressed. Moreover, they reported a significant positive correlation between ICG R15 and local oxygen consumption in alcoholic liver disease, suggesting a close association between HBF and local oxygen consumption and, by extension, liver-sparing ability in CLD. Additionally, portal flow increases and intestinal hemodynamics improve as a result of interrupted blood flow to the collateral vessels. By inference, these phenomena may result in increased estimated hepatic oxygen consumption, hepatocyte function, and synthesis.

 There are some reports which relate HBF to liver function. [Noiret](http://www.ncbi.nlm.nih.gov/pubmed?term=Noiret%20L%5BAuthor%5D&cauthor=true&cauthor_uid=24134128) *et al*[30] reported that the redistribution of organ blood flow associated with severe cirrhosis was sufficient to cause hyperammonemia, even when the hepatic detoxification function and the ammonia production were set to normal. They noted that interventions that reduce the fraction of shunting may be future targets of therapy to control hyperammonemia severity. Maruyama *et al*[31] reported that patients with hepatofugal flow had a significantly higher incidence of ascites than those with hepatopetal flow, higher Child-Pugh classification, and higher incidence of decompensated liver and rectal varices. Two reports suggest that depending on the severity of portal hypertension, decrease of HBF can lead to deteriorate liver function in spite of relatively preserving hepatocellular function. In addition, we reported that PVTBF increased after endoscopic injection sclerotherapy for EGV, and HATBF decreased in response to an increase in PVTBF[12]. In the future, we will elucidate whether hemodynamic alteration leads to the amelioration of liver function.

 In conclusion, there is a significant close correlation between PVTBF, ICG R15, and liver function.

**ACKNOWLEDGMENTS**

The authors wish to thank the technical assistants at the Imaging Center of St. Marianna University School of Medicine Hospital for their assistance.

**COMMENTS**

***Background***

Hepatic blood flow (HBF) generally decreases with disease progression inchronic liver disease. Additionally collateral vessel appear and liver function, such as liver synthesis and disposal capability, declines in liver cirrhosis (LC).

***Research frontiers***

Notably in LC it is known that liver function deteriorates in almost direct proportion to progression of liver disease such as Child-Pugh classification. Thus, in order to assess the state of chronic liver disease it is very important to evaluate HBF.

***Innovations and breakthroughs***

The aim of the present study was to measure liver function and HBF using xenon computed tomography, and elucidate the correlation between HBF and liver function in alcoholic LC.

***Peer review***

The study is an interesting exploration of how hepatic perfusion may relate to liver function.

**REFERENCES**

1 **Gur D**, Good WF, Wolfson SK, Yonas H, Shabason L. In vivo mapping of local cerebral blood flow by xenon-enhanced computed tomography. *Science* 1982; **215**: 1267-1268 [PMID: 7058347 DOI: 10.1126/science.7058347]

2 **Leopold D**, Zinreich SJ, Simon BA, Cullen MM, Marcucci C. Xenon-enhanced computed tomography quantifies normal maxillary sinus ventilation. *Otolaryngol Head Neck Surg* 2000; **122**: 422-424 [PMID: 10699821 DOI: 10.1016/S0194-5998(00)70059-3]

3 **Sase S**, Suzuki M, Ikeda H, Takahashi H, Okuse N, Maeyama S, Shibata I. Quantitative multilevel mapping of hepatic blood flow by xenon computed tomography using aorta. *J Comput Assist Tomogr* 2003; **27**: 647-651 [PMID: 12886161 DOI: 10.1097/00004728-200307000-00037]

4 **Ikeda H**, Suzuki M, Kobayashi M, Takahashi H, Matsumoto N, Maeyama S, Iino S, Sase S, Itoh F. Xenon computed tomography shows hemodynamic change during the progression of chronic hepatitis C. *Hepatol Res* 2007; **37**: 104-112 [PMID: 17300705 DOI: 10.1111/j.1872-034X.2007.00020.x]

5 **Takahashi H**, Suzuki M, Ikeda H, Kobayashi M, Sase S, Yotsuyanagi H, Maeyama S, Iino S, Itoh F. Evaluation of quantitative portal venous, hepatic arterial, and total hepatic tissue blood flow using xenon CT in alcoholic liver cirrhosis: comparison with liver cirrhosis C. *Alcohol Clin Exp Res* 2007; **31**: S43-S48 [PMID: 17331165 DOI: 10.1111/j.1530-0277.2006.00285.x]

6 **Kobayashi M**, Suzuki M, Ikeda H, Takahashi H, Matsumoto N, Maeyama S, Sase S, Iino S, Itoh F. Assessment of hepatic steatosis and hepatic tissue blood flow by xenon computed tomography in nonalcoholic steatohepatitis. *Hepatol Res* 2009; **39**: 31-39 [PMID: 18761681 DOI: 10.1111/j.1872-034X.2008.00407.x]

7 **Takahashi H**, Suzuki M, Ikeda H, Kobayashi M, Sase S, Yotsuyanagi H, Maeyama S, Iino S, Itoh F. Evaluation of quantitative portal venous, hepatic arterial, and total hepatic tissue blood flow using xenon CT in alcoholic liver cirrhosis-comparison with liver cirrhosis related to hepatitis C virus and nonalcoholic steatohepatitis. *Alcohol Clin Exp Res* 2010; **34 Suppl 1**: S7-S13 [PMID: 18986379 DOI: 10.1111/j.1530-0277.2008.00755.x]

8 **Sase S**, Monden M, Oka H, Dono K, Fukuta T, Shibata I. Hepatic blood flow measurements with arterial and portal blood flow mapping in the human liver by means of xenon CT. *J Comput Assist Tomogr* 2002; **26**: 243-249 [PMID: 11884781 DOI: 10.1097/00004728-200203000-00014]

9 **Sase S**, Takahashi H, Ikeda H, Kobayashi M, Matsumoto N, Suzuki M. Determination of time-course change rate for arterial xenon using the time course of tissue xenon concentration in xenon-enhanced computed tomography. *Med Phys* 2008; **35**: 2331-2338 [PMID: 18649466 DOI: 10.1118/1.2912021]

10 **Shigefuku R**, Takahashi H, Kobayashi M, Ikeda H, Matsunaga K, Okuse C, Matsumoto N, Maeyama S, Sase S, Suzuki M, Itoh F. Pathophysiological analysis of nonalcoholic fatty liver disease by evaluation of fatty liver changes and blood flow using xenon computed tomography: can early-stage nonalcoholic steatohepatitis be distinguished from simple steatosis? *J Gastroenterol* 2012; **47**: 1238-1247 [PMID: 22576023 DOI: 10.1007/s00535-012-0581-4]

11 **Sase S**, Takahashi H, Shigefuku R, Ikeda H, Kobayashi M, Matsumoto N, Suzuki M. Measurement of blood flow and xenon solubility coefficient in the human liver by xenon-enhanced computed tomography. *Med Phys* 2012; **39**: 7553-7559 [PMID: 23231303 DOI: 10.1118/1.4767759]

12 **Takahashi H**, Suzuki M, Shigefuku R, Okano M, Hiraishi T, Takagi R, Noguchi Y, Hattori N, Hatsugai M, Nakahara K, Okamoto M, Kobayashi M, Ikeda H, Fukuda Y, Nagase Y, Ishii T, Matsunaga K, Matsumoto N, Okuse C, Sase S, Itoh F. Xenon computed tomography can evaluate the improvement of hepatic hemodynamics before and after endoscopic injection sclerotherapy. *J Gastroenterol* 2013; **48**: 1353-1361 [PMID: 23397117 DOI: 10.1007/s00535-013-0756-7]

13 **Shigefuku R**, Takahashi H, Kato M, Yoshida Y, Suetani K, Noguchi Y, Hatsugai M, Nakahara K, Ikeda H, Kobayashi M, Matsunaga K, Matsumoto N, Okuse C, Itoh F, Maeyama S, Sase S, Suzuki M. Evaluation of hepatic tissue blood flow using xenon computed tomography with fibrosis progression in nonalcoholic fatty liver disease: comparison with chronic hepatitis C. *Int J Mol Sci* 2014; **15**: 1026-1039 [PMID: 24424317 DOI: 10.3390/ijms15011026]

14 **Annet L**, Materne R, Danse E, Jamart J, Horsmans Y, Van Beers BE. Hepatic flow parameters measured with MR imaging and Doppler US: correlations with degree of cirrhosis and portal hypertension. *Radiology* 2003; **229**: 409-414 [PMID: 12970464 DOI: 10.1148/radiol.2292021128]

15 **Bernatik T**, Strobel D, Hahn EG, Becker D. Doppler measurements: a surrogate marker of liver fibrosis? *Eur J Gastroenterol Hepatol* 2002; **14**: 383-387 [PMID: 11943950 DOI: 10.1097/00042737-200204000-00008]

16 **Fujita Y**, Watanabe M, Sasao K, Wakui N, Shinohara M, Ishii K, Sumino Y. Investigation of liver parenchymal flow using contrast-enhanced ultrasound in patients with alcoholic liver disease. *Alcohol Clin Exp Res* 2004; **28**: 169S-173S [PMID: 15318107 DOI: 10.1111/j.1530-0277.2004.tb03238.x]

17 **Hirata M**, Kurose K, Minami H, Kumagi T, Akbar SM, Michitaka K, Horiike N, Onji M. Clinical characteristics of portal hemodynamics in alcoholic liver cirrhosis. *Alcohol Clin Exp Res* 2004; **28**: 148S-152S [PMID: 15318103 DOI: 10.1111/j.1530-0277.2004.tb03234.x]

18 **Chiandussi L**, Greco F, Sardi G, Vaccarino A, Ferraris CM, Curti B. Estimation of hepatic arterial and portal venous blood flow by direct catheterization of the vena porta through the umbilical cord in man. Preliminary results. *Acta Hepatosplenol* 1968; **15**: 166-171 [PMID: 4878405]

19 **Materne R**, Smith AM, Peeters F, Dehoux JP, Keyeux A, Horsmans Y, Van Beers BE. Assessment of hepatic perfusion parameters with dynamic MRI. *Magn Reson Med* 2002; **47**: 135-142 [PMID: 11754452 DOI: 10.1002/mrm.10045]

20 **Van Beers BE**, Leconte I, Materne R, Smith AM, Jamart J, Horsmans Y. Hepatic perfusion parameters in chronic liver disease: dynamic CT measurements correlated with disease severity. *AJR Am J Roentgenol* 2001; **176**: 667-673 [PMID: 11222202 DOI: 10.2214/ajr.176.3.1760667]

21 **VISSCHER MB**, JOHNSON JA. The Fick principle: analysis of potential errors in its conventional application. *J Appl Physiol* 1953; **5**: 635-638 [PMID: 13044747]

22 **Hayashi N**, Kasahara A, Kurosawa K, Sasaki Y, Fusamoto H, Sato N, Kamada T. Oxygen supply to the liver in patients with alcoholic liver disease assessed by organ-reflectance spectrophotometry. *Gastroenterology* 1985; **88**: 881-886 [PMID: 3972232]

23 **Kasahara A**, Hayashi N, Kurosawa K, Sasaki Y, Sato N, Kamada T. Hepatic hemodynamics and oxygen consumption in alcoholic fatty liver assessed by organ-reflectance spectrophotometry and the hydrogen clearance method. *Hepatology* 1986; **6**: 87-91 [PMID: 3943793 DOI: 10.1002/hep.1840060116]

24 **Witte CL**, Witte MH, Krone CL. Contrasting hemodynamic patterns of portal hypertension. *Ann Surg* 1972; **176**: 68-79 [PMID: 4537675 DOI: 10.1097/00000658-197207000-00014]

25 **Newby DE**, Hayes PC. Hyperdynamic circulation in liver cirrhosis: not peripheral vasodilatation but 'splanchnic steal'. *QJM* 2002; **95**: 827-830 [PMID: 12454326 DOI: 10.1093/qjmed/95.12.827]

26 **Richter S**, Mücke I, Menger MD, Vollmar B. Impact of intrinsic blood flow regulation in cirrhosis: maintenance of hepatic arterial buffer response. *Am J Physiol Gastrointest Liver Physiol* 2000; **279**: G454-G462 [PMID: 10915656]

27 **Gülberg V**, Haag K, Rössle M, Gerbes AL. Hepatic arterial buffer response in patients with advanced cirrhosis. *Hepatology* 2002; **35**: 630-634 [PMID: 11870377 DOI: 10.1053/jhep.2002.31722]

28 **Berzigotti A**, Reverter E, García-Criado A, Abraldes JG, Cerini F, García-Pagán JC, Bosch J. Reliability of the estimation of total hepatic blood flow by Doppler ultrasound in patients with cirrhotic portal hypertension. *J Hepatol* 2013; **59**: 717-722 [PMID: 23669282 DOI: 10.1016/j.jhep.2013.04.037]

29 **Tygstrup N**, Winkler K, Mellemgaard K, Andreassen M. Determination of the hepatic arterial blood flow and oxygen supply in man by clamping the hepatic artery during surgery. *J Clin Invest* 1962; **41**: 447-454 [PMID: 13923352 DOI: 10.1172/JCI104497]

30 **Noiret L**, Baigent S, Jalan R. Arterial ammonia levels in cirrhosis are determined by systemic and hepatic hemodynamics, and by organ function: a quantitative modelling study. *Liver Int* 2013; Epub ahead of print [PMID: 24134128 DOI: 10.1111/liv.12361]

31 **Maruyama H**, Kamezaki H, Kondo T, Sekimoto T, Shimada T, Takahashi M, Okugawa H, Yokosuka O. Effects of inferior mesenteric vein flow in patients with cirrhosis. *Clin Gastroenterol Hepatol* 2013; **11**: 1648-1654 [PMID: 23876594 DOI: 10.1016/j.cgh.2013.06.026]

 **P-Reviewers:** Abbott DE, Jie SH, ZhangYP **S-Editor:** Gou SX

**L-Editor: E-Editor:**

**Figure 1 Schema of the dual supply model and the basic equation for hepatic blood flow of xenon computed tomography.** Based on the changes over time in CT values for the hepatic tissues and the spleen, hepatic tissue blood flow TBF was calculated by applying the Fick principle using Kety-Schmidt’s equation to obtain arterial blood flow (*fa*), portal blood flow (*fp*), and lambda (*λ*) values in the human liver on a pixel-by-pixel basis in xenon computed tomography (Xe-CT). This dual blood supply model for the liver was used to calculate hepatic blood flow by Xe-CT. Ch(*t*), Ca(*t*), Cv(*t*), and Cpv(*t*) represent time-dependent Xe concentrations in the liver tissue, arterial blood, venous blood, and portal blood, respectively. Arterial and portal blood flows per unit volume of liver tissue are indicated by *fa* and *fp*, respectively. Cp(*t*) represents the time-dependent Xe concentration in the portal organ tissue, and fpa indicates blood flow per unit volume of portal organ tissue.

**Figure 2 Measuring methods of hepatic tissue blood flows using xenon computed tomography.** Xenon concentration in inhaled gas was 25%, and a 4-min wash-in and 4-min wash-out were used. Computed tomography (CT) at each of the 4 levels was performed 8 times at 1-min intervals. Patients held their breath during each scan to prevent movement of the liver caused by respiration. CT of the spleen was used to measure arterial xenon concentrations.

**Figure 3 Measurement of hepatic tissue blood flows and confidence values obtained using xenon computed tomography.** A: Baseline computed tomography; B: Confidence map. The original blood flow maps were modified by automatically excluding any pixels with confidence values exceeding the threshold in the confidence map. The white areas on the confidence map indicate regions of low reliability and were automatically excluded. Confidence values indicate the difference between theoretical and actual changes over time on xenon computed tomography (Xe-CT); C: Portal tissue blood flow (PVTBF) map; D: Hepatic arterial tissue blood flow (HATBF) map; E: Total hepatic tissue blood flow (THTBF) map. Maps were created for portal venous TBF (PVTBF; C), hepatic arterial TBF (HATBF; D), the Xe solubility coefficient, and confidence values for each pixel in the liver based on changes over time in the Xe-CT numbers in the hepatic tissue and spleen.

**Figure 4 Measurement of hepatic tissue blood flow using xenon computed tomography.** Measurement of hepatic tissue blood flows (TBF) and confidence values obtained using xenon computed tomography (Xe-CT). Maps were created for portal venous TBF (PVTBF; C), hepatic arterial TBF (HATBF; D), the Xe solubility coefficient (B), and confidence values for each pixel in the liver on the basis of changes over time in the Xe-CT numbers in the hepatic tissue and spleen. A: Confidence map. The original blood flow maps were modified by automatically excluding any pixels with confidence values exceeding the threshold in the confidence map. The white areas on the confidence map indicate regions of low reliability and were automatically excluded. Confidence values indicate the difference between theoretical and actual changes over time on Xe-CT; B: The lambda map shows the Xe solubility in the tissue; C: Portal blood flow map; D: Arterial blood flow map; E: Total hepatic tissue blood flow (THTBF) map. The color in each blood flow map changes from blue to red with increasing blood flow.

**Figure 5 Correlation between portal venous tissue blood flow and retention rate of indocyanine green 15 min after administration.** Portal venous tissue blood flow (PVTBF) was significantly negatively correlated with retention rate of indocyanine green 15 min after administration (ICG R15) (*r* = -0.442, *P* < 0.01).

**Figure 6 Correlation between albumin, ammonia, and venous tissue blood flow.** There was a significant correlation between portal venous tissue blood flow (PVTBF) and albumin (Alb) (*r* = 0.2499, *P* < 0.05) (A) and ammonia (NH3) tended to have an inverse correlation with PVTBF (*r* = -0.2428, *P* = 0.0894) (B).

**Figure 7 Correlation between liver function and retention rate of indocyanine green 15 min after administration.** There were many significant correlations between retention rate of indocyanine green 15 min after administration (ICG R15) and liver function parameters, including albumin (Alb) (A), ammonia (NH3) (B), prothrombin time (PT) (C), brain natriuretic peptide (BNP) (D), total bile acid (TBA) (E), branched-chain amino acids (BCAA) (F), and tyrosine (G).

**Table 1 Characteristics of patients with alcoholic liver cirrhosis**

|  |  |
| --- | --- |
| **Characteristics** |  |
| Patients (*n*) |  |  |
| Gender | Male | 34 |
|  | Female | 1 |
| Age (yr) |  |  |
|  | Average | 58.9 ± 10.7 |
|  | Range | 37-76 |
|  | Median | 61 |

Data represent raw number of patients or mean ± SD.

**Table 2 Hepatic tissue blood flow, retention rate of indocyanine green 15 min after administration, and liver function**

|  |  |  |
| --- | --- | --- |
| PVTBF |  (mL/100 mL/min) | 30.2 ± 10.4 |
| HATBF  |  (mL/100mL/min) | 20.0 ± 10.7 |
| THTBF  |  (mL/100 mL/min) | 50.3 ± 14.9 |
| Alb |  (g/dL) | 3.50 ± 0.50 |
| PT |   | 72.0% ± 11.5% |
| ChE |  (IU/L) | 161.0 ± 70.8 |
| BNP | (pg/mL) | 63.2 ± 56.7 |
| TBA | (μmol/L) | 68.0 ± 51.8 |
| NH3 |  (μg/dL) | 59.4 ± 22.7 |
| ICG R15  |  | 28.6% ± 13.5% |
| BTR |  | 4.06 ± 1.24 |
| BCAA |  (μmol/L) | 437.5 ± 89.4 |
| Tyrosine |  (μmol/L) | 117.7 ± 32.8 |
| IRI |  (μg/dL) | 12.8 ± 5.0 |

Data represent mean ± Standard deviation. PVTBF: Portal venous tissue blood flow; HATBF: Hepatic arterial tissue blood flow; THTBF: Total hepatic tissue blood flow; ICG R15: Retention rate of indocyanine green 15 min after administration; Alb: Albumin; PT: Prothrombin time; BNP: Brain natriuretic peptide; BTR: Branched amino acid and tyrosine ratio; NH3: Ammonia; ChE: Cholinesterase; IRI: Immunoreactive insulin; TBA: Total bile acid.

**Table 3 Correlation between hepatic tissue blood flow, retention rate of indocyanine green 15 min after administration, and liver function**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **PVBTF** |  | **HATBF** |  | **THTBA** |  | **ICG R15** |  |
|  | ***r*** | ***P*** | ***r*** | ***P*** | ***r*** | ***P*** | ***r*** | ***P*** |
| Alb (g/dL) | 0.2499 | < 0.05 | -0.0251 | NS | 0.0452 | N.S. | -0.2156 | < 0.05 |
| NH3 (μg/dL) | -0.2428 | 0.0894 | -0.1479 | NS | -0.1307 | N.S. | 0.4318 | < 0.01 |
| PT  | 0.1475 | NS | 0.1947 | NS | 0.0690 | NS | -0.4140 | < 0.01 |
| BNP (pg/mL) | -0.0231 | NS | -0.0231 | NS | 0.0330 | NS | 0.3610 | < 0.05 |
| TBA (μmol/L) | -0.1810 | NS | -0.0160 | NS | 0.0483 | NS | 0.5085 | < 0.01 |
| T Chol (mg/dL) | -0.0618 | NS | 0.2007 | NS | 0.0483 | NS | 0.4195 | < 0.05 |
| ChE (IU/L) | -0.0613 | NS | 0.0704 | NS | 0.0197 | NS | -0.0952 | NS |
| BTR | -0.1329 | NS | 0.2103 | NS | 0.0801 | NS | -0.2378 | NS |
| BCAA (μmol/L) | -0.3123 | NS | 0.2031 | NS | -0.0220 | NS | 0.4496 | < 0.01 |
| Tyrosine (μmol/L) | 0.0644 | NS | -0.0317 | NS | -0.0078 | NS | 0.4740 | < 0.01 |
| IRI (μg/dL) | -0.0377 | NS | 0.0509 | NS | -0.0509 | NS | 0.1251 | NS |

PVTBF: Portal venous tissue blood flow; HATBF: Hepatic arterial tissue blood flow; THTBF: Total hepatic tissue blood flow; Alb: Albumin; PT: Prothrombin time; BNP: Brain natriuretic peptide; BTR: Branched amino acid and tyrosine ratio; NH3: Ammonia; ChE: Cholinesterase; IRI: Immunoreactive insulin; TBA: Total bile acid; BCAA: BCAA: Branched-chain amino acids; NS: Not significant.